Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Worldwide, each year over 30,000 patients undergo an allogeneic hema-topoietic stem cell
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …

Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders,
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …

With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–
mobilized peripheral blood stem cell donor grafts and successful treatment of older …

Posttransplantation cyclophosphamide (PTCy) is an effective prophylaxis against graft-
versus-host disease (GVHD). However, it is unknown whether PTCy works singularly by …

Chronic graft-versus-host disease (cGVHD) remains a major complication following
allogeneic bone marrow transplantation (BMT). The discovery of novel therapeutics is …

Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic
hematopoietic stem cell transplantation, and current therapies do not completely prevent …

Allogeneic hematopoietic stem cell transplantation is hampered by chronic graft-versus-host
disease (cGVHD), resulting in multiorgan fibrosis and diminished function. Fibrosis in lung …

STAT3 deficiency (STAT3–/–) in donor T cells prevents graft-versus-host disease (GVHD),
but the impact on graft-versus-leukemia (GVL) activity and mechanisms of GVHD prevention …

Novel therapies for chronic graft-versus-host disease (cGVHD) are needed. Aberrant B-cell
activation has been demonstrated in mice and humans with cGVHD. Having previously …